Skip to main content
COGT logo

COGT · Cogent Biosciences, Inc.

Track COGT — free
$26.72 -1.03 (-3.70%) At close · Nov 20
Market Cap
$4.65B
Shares
173.99M
Volume · Nov 20 2.13M Avg daily vol (3M) 2.08M

Price & Indicators

 

Key stats

Close
$26.72
Fri 20 Nov
Open
$27.26
Fri 20 Nov
Average volume, 30 days
2.2M
shares a session
Short interest
17.4M
10.0% of shares · 8.7 days to cover
Day range
$26.62$27.83
Open $27.26 Close $26.72
52-week closing range
$26.72$42.84
Close $26.72 37.6% under the high
Short volume, last session
22%
Last earnings
Nov 5, 2026
Latest filing
10-Q · Nov 5
Price history
Jan 2020 to Nov 2026

Up next

May 4, 2027 Est · unconfirmed · in 23 wks

Latest documents

2026
Nov 17
Investor event
Management Expects Bezuclastinib Approval as PDUFA Dates Approach

Cogent Biosciences management says it expects FDA approval of bezuclastinib, with PDUFA dates of November 30th, December 30th and June 29th of 2027. Liver transaminase elevations are described as fluctuating, with no significant clinical sequelae.

4 source passages
we're expecting it with pending PDUFA action dates of November 30th, December 30th, and June 29th of 2027 for just non-advanced and advanced in that order the profile is of fluctuating transaminases we are not associated with significant clinical sequelae in response to the elevated transaminases Open the document at this passage
Nov 17
Investor event
Bezuclacinib Faces Three FDA Decisions, First PDUFA Date November 30

Cogent's lead drug bezuclacinib has PDUFA dates of November 30 for imatinib-resistant GIST, December 30 for non-advanced systemic mastocytosis, and June 29, 2027 for advanced systemic mastocytosis. The company says it is ready to ship product within two or three days of approval.

6 source passages
we have formal PDUFA dates announced, and they remain in place for all three with a November 30th on December 30th, a PDUFA date for the non-advanced systemic mastocytosis indication for the advanced form of mastocytosis, which is June 29th of 2027 we estimate there to be between 2,500 and 3,000 patients a year who develop resistance to imatinib we think that the workflow for these patients in a commercial setting is going to be nearly identical we'll be able to ship product to the first customer within two days, two or three days of approval Open the document at this passage
Nov 10
Investor event
Bezuclacinib nearing FDA approval with launch readiness established

Cogent says bezuclacinib is days away from FDA approval, with November 30th set as the first PDUFA date for GIST. Commercial teams are in place, and orders could begin within a day or two of clearance.

4 source passages
we've been developing a drug called bezuclacinib, which is a selective potent KIT inhibitor for three different patient populations within systemic mastocytosis, both the non-advanced and advanced form of the disease, and then in gastrointestinal stromal tumors for patients who have developed resistance on imatinib therapy. Obviously, again, the first PDUFA date for the GIST opportunity is November 30th. And so we have our entire home office commercial team and medical teams in place long ago, and then in Q3, we onboarded all of our field professionals who have territories around the country, and they've been working very hard to develop relationships, doing introductions, telling people who Cogent is, and getting ready for the day when they're ready to sell the product. it's probably a matter of a day or two would be my guess from the time we get the green light. There's some logistical things about having to move from place A to place B, which you can only do once a product is released and commercial, but it is literally a handful of days and we would start taking orders immediately. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Three bezuclastinib FDA reviews loom; cash runway extends into late 2028

Cogent has three bezuclastinib NDAs pending FDA review, with PDUFA target dates November 30, 2026, December 30, 2026 and June 29, 2027. Cash, cash equivalents and marketable securities of $791.1 million were expected to fund operations into late 2028.

Net loss $111.43M Diluted EPS -$0.59
Read from the MD&A section
6 source passages
In 2025, we reported positive top-line results from registrational trials in each of these indications, and we subsequently filed three New Drug Applications (each, an “NDA”) that are all currently pending review with the U.S. Food and Drug Administration (“FDA”). We submitted the first NDA for bezuclastinib in patients with NonAdvSM in December 2025, which was accepted by the FDA in March 2026. The FDA assigned a Prescription Drug User Fee Act ("PDUFA") target action date of December 30, 2026. We submitted an NDA in June 2026 for patients with AdvSM, which was accepted by the FDA in September 2026. The FDA assigned a PDUFA target action date of June 29, 2027. In January 2026, we announced that the FDA agreed to accept our NDA for bezuclastinib in combination with sunitinib for patients with GIST who have received prior treatment with imatinib under the Real-Time Oncology Review ("RTOR") program and we submitted our GIST NDA in March 2026 under this program, which was accepted by the FDA with Priority Review in May 2026. The FDA assigned a PDUFA target action date of November 30, 2026. As of September 30, 2026, we had cash, cash equivalents and marketable securities of $791.1 million. We believe that our cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements into late 2028, well past all three pending PDUFA action dates for bezuclastinib. The Cogent Research Team is also developing additional targeted therapies to help patients fighting serious, genetically driven diseases, including programs targeting mutations in KRAS and JAK2. Open the document at this passage
Nov 5
Current report 8-K
Bezuclastinib faces FDA decision in GIST on November 30, 2026

Cogent Biosciences reported a $111.4 million 2026 third-quarter net loss and $791.1 million cash. Bezuclastinib FDA decision dates are November 30, 2026 for GIST, December 30, 2026 for NonAdvSM and June 29, 2027 for AdvSM.

Financial results
5 source passages
Net loss was $111.4 million for the third quarter of 2026 as compared to a net loss of $80.9 million for the same period of 2025. Cash Position: As of September 30, 2026, cash, cash equivalents and marketable securities were $791.1 million, as compared to $792.3 million as of June 30, 2026. Potential FDA approval of bezuclastinib in GIST – PDUFA date of November 30, 2026 Potential FDA approval of bezuclastinib in NonAdvSM – PDUFA date of December 30, 2026 Potential FDA approval of bezuclastinib in AdvSM – PDUFA date of June 29, 2027 Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$407.68M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-7.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$6.28M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+25.9%
Year over year · more shares
Price change (1Y)
-23.0%
Trailing year
Short interest
10.0%
Latest settlement · 8.7 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −24%
below
Price vs 50-day avg −13%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −14%
trailing
6-month return −18%
trailing
YTD return −25%
this year
Relative strength −9%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $31 › 200d $35 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +49 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
10.01% of shares out · ▼ -11.4% MoM · 8.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
319 holders — mid 3-yr range
Squeeze score 61
elevated · 0–100
Fundamentals
Weak
Revenue growth −65%
Y/Y
EPS growth −11%
Y/Y
Free cash flow $-266.0M
Balance sheet $89.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 46%
annualized · 1-yr
Max drawdown −38%
past year
ATR 5.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−24% Bearish
Price vs 50-day avg
−13% Bearish
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $31 › 200d $35 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +49 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
10.01% of shares out · ▼ -11.4% MoM · 8.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
319 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $27 Now $27 · 0% Range high $43
vs 200-day avg -24% vs 50-day avg -13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
COGT
Cogent Biosciences, Inc.
this stock
$4.65B -24.8% -65.0% — 10.0%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
319
% held
115.1%
Net QoQ
+6.6M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
373
View
Short & Settlement
Short Interest Falling
Shares short
17.4M
Days to cover
8.7d
Change
-2.2M sh
View
Short Volume
Short vol %
22%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
100
Value
$3.1K
As of
Oct 22, 2026
View
Off-Exchange
Off-exchange %
44.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Christopher L. Jacobs
Amount
$1.0K–$15.0K
Traded
Dec 12, 2022
View
Financials
Financials
Net income (FY)
$-328.9M
EPS diluted
$-2.16
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
18

Cogent Biosciences management says it expects FDA approval of bezuclastinib, with PDUFA dates of November 30th, December 30th and June 29th of 2027. Liver transaminase elevations are described as fluctuating, with no significant clinical sequelae.

View
Proposed Sales
Value
$1.7M
Shares
45.5K
Filed
Aug 27, 2026
View
Exempt Offerings
Offering
$104.4M
Filed
Jul 21, 2020
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 11, 2026
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Cogent Biosciences Reports Recent…
Published
Nov 5, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
COGT -6.5% -14.4% -18.5% -13.9% -24.8%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +2.1% -5.2% -9.3% -5.2% -26.0%
Key facts CIK 1622229 CUSIP 19240Q201 13F (30d) 323 filings 300 filers Visit website Investor relations